Your browser doesn't support javascript.
loading
First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants.
Coudert, Marie; Drouet, Youenn; Delhomelle, Hélène; Svrcek, Magali; Benusiglio, Patrick R; Coulet, Florence; Clark, Dana Farengo; Katona, Bryson W; van Hest, Liselotte P; van der Kolk, Lizet E; Cats, Annemieke; van Dieren, Jolanda M; Nehoray, Bita; Slavin, Thomas; Spier, Isabel; Hüneburg, Robert; Lobo, Silvana; Oliveira, Carla; Boussemart, Lise; Masson, Laure; Chiesa, Jean; Schwartz, Mathias; Buecher, Bruno; Golmard, Lisa; Bouvier, Anne-Marie; Bonadona, Valérie; Stoppa-Lyonnet, Dominique; Lasset, Christine; Colas, Chrystelle.
  • Coudert M; Département de Génétique, Institut Curie, Paris, France.
  • Drouet Y; CNRS UMR 5558 LBBE, Université de Lyon, Villeurbanne, France.
  • Delhomelle H; Département Prévention et Santé Publique, Centre Léon Bérard, Lyon, France.
  • Svrcek M; Département de Génétique, Institut Curie, Paris, France.
  • Benusiglio PR; AP-HP, Saint-Antoine Hospital, Department of Pathology, Sorbonne Université, Paris, France.
  • Coulet F; Département de Génétique Médicale, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.
  • Clark DF; Département de Génétique Médicale, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.
  • Katona BW; Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • van Hest LP; Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • van der Kolk LE; Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Cats A; Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Dieren JM; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nehoray B; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Slavin T; Division of Clinical Cancer Genomics, City of Hope, Duarte, California, USA.
  • Spier I; Departments of Medical Oncology and Population Sciences, City of Hope, Duarte, California, USA.
  • Hüneburg R; Institute of Human Genetics/National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
  • Lobo S; Department of Internal Medicine/National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
  • Oliveira C; IPATIMUP-Institut of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.
  • Boussemart L; i3s, Universidade do Porto Instituto de Investigação e Inovação em Saúde, Porto, Portugal.
  • Masson L; Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.
  • Chiesa J; Faculty of Medicine, University of Porto, Porto, Portugal.
  • Schwartz M; Service de Dermatologie, Hotel Dieu, Nantes, France.
  • Buecher B; Dermatologie, CHU Rennes, Rennes, France.
  • Golmard L; Génétique, Hopital Universitaire Caremeau, Nimes, France.
  • Bouvier AM; Département de Génétique, Institut Curie, Paris, France.
  • Bonadona V; Département de Génétique, Institut Curie, Paris, France.
  • Stoppa-Lyonnet D; Département de Génétique, Institut Curie, Paris, France.
  • Lasset C; Digestive Cancer Registry of Burgundy, UMR 1231, Réseau FRANCIM (réseau Français des registres du cancer), Burgundy Franche-Comté University, Dijon, France.
  • Colas C; CNRS UMR 5558 LBBE, Université de Lyon, Villeurbanne, France.
J Med Genet ; 59(12): 1189-1195, 2022 12.
Article en En | MEDLINE | ID: mdl-36038258
ABSTRACT

BACKGROUND:

Pathogenic variants (PV) of CTNNA1 are found in families fulfilling criteria for hereditary diffuse gastric cancer (HDGC) but no risk estimates were available until now. The aim of this study is to evaluate diffuse gastric cancer (DGC) risks for carriers of germline CTNNA1 PV.

METHODS:

Data from published CTNNA1 families were updated and new families were identified through international collaborations. The cumulative risk of DGC by age for PV carriers was estimated with the genotype restricted likelihood (GRL) method, taking into account non-genotyped individuals and conditioning on all observed phenotypes and genotypes of the index case to obtain unbiased estimates. A non-parametric (NP) and the Weibull functions were used to model the shape of penetrance function with the GRL. Kaplan-Meier incidence curve and standardised incidence ratios were also computed. A 'leave-one-out' strategy was used to evaluate estimate uncertainty.

RESULTS:

Thirteen families with 46 carriers of PV were included. The cumulative risks of DGC at 80 years for carriers of CTNNA1 PV are 49% and 57%, respectively with the Weibull GRL and NP GRL methods. Risk ratios to population incidence reach particularly high values at early ages and decrease with age. At 40 years, they are equal to 65 and 833, respectively with the Weibull GRL and NP GRL.

CONCLUSION:

This is the largest series of CTNNA1 families that provides the first risk estimates of GC. These data will help to improve management and surveillance for these patients and support inclusion of CTNNA1 in germline testing panels.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article